{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:24:07Z","timestamp":1780493047190,"version":"3.54.1"},"reference-count":45,"publisher":"Portland Press Ltd.","issue":"5","license":[{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"vor","delay-in-days":303,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,10,31]]},"abstract":"<jats:p>There is increasing evidence that serum adipokine levels are associated with higher risks of cardiovascular diseases. As an important adipokine, fibroblast growth factor 21 (FGF21) has been demonstrated to be associated with atherosclerosis and coronary artery disease (CAD). However, circulating level of FGF21 in patients with angina pectoris has not yet been investigated. Circulating FGF21 level was examined in 197 patients with stable angina pectoris (SAP, n=66), unstable angina pectoris (UAP, n=76), and control subjects (n=55) along with clinical variables of cardiovascular risk factors. Serum FGF21 concentrations on admission were significantly increased more in patients with UAP than those with SAP (Ln-FGF21: 5.26 \u00b1 0.87 compared with 4.85 \u00b1 0.77, P&amp;lt;0.05) and control subjects (natural logarithm (Ln)-FGF21: 5.26 \u00b1 0.87 compared with 4.54 \u00b1 0.72, P&amp;lt;0.01). The correlation analysis revealed that serum FGF21 concentration was positively correlated with the levels of cardiac troponin I (cTnI) (r2\u2009 = \u20090.026, P=0.027) and creatine kinase-MB (CK-MB) (r2\u2009 = \u20090.023, P=\u20090.04). Furthermore, FGF21 level was identified as an independent factor associated with the risks of UAP (odds ratio (OR): 2.781; 95% CI: 1.476\u20135.239; P=0.002), after adjusting for gender, age, and body mass index (BMI). However, there were no correlations between serum FGF21 levels and the presence of SAP (OR: 1.248; 95% CI: 0.703\u20132.215; P=0.448). The present study indicates that FGF21 has a strong correlation and precise predictability for increased risks of UAP, that is independent of traditional risk factors of angina pectoris.<\/jats:p>","DOI":"10.1042\/bsr20181099","type":"journal-article","created":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T17:18:14Z","timestamp":1536167894000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Circulating level of fibroblast growth factor 21 is independently associated with the risks of unstable angina pectoris"],"prefix":"10.1042","volume":"38","author":[{"given":"Jing","family":"Cheng","sequence":"first","affiliation":[{"name":"The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health and The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Shandong University Qilu Hospital, Jinan City, Shandong Province, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Su","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health and The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Shandong University Qilu Hospital, Jinan City, Shandong Province, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Qiao","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health and The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Shandong University Qilu Hospital, Jinan City, Shandong Province, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chungang","family":"Zhai","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health and The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Shandong University Qilu Hospital, Jinan City, Shandong Province, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Chen","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health and The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Shandong University Qilu Hospital, Jinan City, Shandong Province, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2018,9,25]]},"reference":[{"key":"2021111619131426300_B1","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrcardio.2014.26","article-title":"Epidemiological studies of CHD and the evolution of preventive cardiology","volume":"11","author":"Wong","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"key":"2021111619131426300_B2","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"GBD 2015 Disease and Injury Incidence and Prevalence Collaborators","year":"2016","journal-title":"Lancet"},{"key":"2021111619131426300_B3","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"GBD 2015 Mortality and Causes of Death Collaborators","year":"2016","journal-title":"Lancet"},{"key":"2021111619131426300_B4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrendo.2013.204","article-title":"Adipose tissue browning and metabolic health","volume":"10","author":"Bartelt","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"2021111619131426300_B5","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrd.2016.75","article-title":"Targeting adipose tissue in the treatment of obesity-associated diabetes","volume":"15","author":"Kusminski","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"2021111619131426300_B6","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jjcc.2013.11.006","article-title":"Adipokines: a link between obesity and cardiovascular disease","volume":"63","author":"Nakamura","year":"2014","journal-title":"J. Cardiol."},{"key":"2021111619131426300_B7","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1152\/physrev.00024.2005","article-title":"Cytokines in atherosclerosis: pathogenic and regulatory pathways","volume":"86","author":"Tedgui","year":"2006","journal-title":"Physiol. Rev."},{"key":"2021111619131426300_B8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.atherosclerosis.2012.12.029","article-title":"Adipokines as mediators of endothelial function and atherosclerosis","volume":"227","author":"Ntaios","year":"2013","journal-title":"Atherosclerosis"},{"key":"2021111619131426300_B9","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00125-014-3210-3","article-title":"Elevated resistin levels induce central leptin resistance and increased atherosclerotic progression in mice","volume":"57","author":"Asterholm","year":"2014","journal-title":"Diabetologia"},{"key":"2021111619131426300_B10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2217\/bmm.13.131","article-title":"Association of plasma leptin, homocysteine and nitric oxide levels with the presence and unstability of coronary artery disease","volume":"8","author":"Basati","year":"2014","journal-title":"Biomarkers Med."},{"key":"2021111619131426300_B11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/1475-2840-12-105","article-title":"Association between serum adipocyte fatty-acid binding protein concentrations, left ventricular function and myocardial perfusion abnormalities in patients with coronary artery disease","volume":"12","author":"Huang","year":"2013","journal-title":"Cardiovasc. Diabetol."},{"key":"2021111619131426300_B12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrd2792","article-title":"The FGF family: biology, pathophysiology and therapy","volume":"8","author":"Beenken","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"2021111619131426300_B13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrd.2015.9","article-title":"Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23","volume":"15","author":"Degirolamo","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"2021111619131426300_B14","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1530\/JOE-15-0289","article-title":"Effects of fibroblast growth factor 21 on the heart","volume":"227","author":"Tanajak","year":"2015","journal-title":"J. Endocrinol."},{"key":"2021111619131426300_B15","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1161\/ATVBAHA.113.301599","article-title":"Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors","volume":"33","author":"Chow","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021111619131426300_B16","doi-asserted-by":"publisher","first-page":"e0129791","DOI":"10.1371\/journal.pone.0129791","article-title":"Serum Level of fibroblast growth factor 21 is independently associated with acute myocardial infarction","volume":"10","author":"Zhang","year":"2015","journal-title":"PLoS ONE"},{"key":"2021111619131426300_B17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cca.2017.07.017","article-title":"Associations of fibroblast growth factor 21 with cardiovascular risk and \u03b2-cell function in patients who had no history of diabetes","volume":"472","author":"Wang","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"2021111619131426300_B18","doi-asserted-by":"publisher","first-page":"4886","DOI":"10.1210\/jc.2016-2308","article-title":"Association between serum fibroblast growth factor 21 and mortality among patients with coronary artery disease","volume":"101","author":"Li","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021111619131426300_B19","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/1475-2840-12-124","article-title":"Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease","volume":"12","author":"Shen","year":"2013","journal-title":"Cardiovasc. Diabetol."},{"key":"2021111619131426300_B20","doi-asserted-by":"publisher","first-page":"H1029","DOI":"10.1152\/ajpheart.00527.2015","article-title":"Fibroblast growth factors in cardiovascular disease: the emerging role of FGF21","volume":"309","author":"Domouzoglou","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2021111619131426300_B21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3109\/07435800.2011.558550","article-title":"Serum FGF-21 levels in type 2 diabetic patients","volume":"36","author":"Cheng","year":"2011","journal-title":"Endocr. Res."},{"key":"2021111619131426300_B22","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005344","article-title":"Role of circulating fibroblast growth factor 21 measurement in primary prevention of coronary heart disease among Chinese patients with type 2 diabetes mellitus","volume":"6","author":"Lee","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"2021111619131426300_B23","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/jhh.2012.52","article-title":"Elevated serum fibroblast growth factor 21 is associated with hypertension in community-dwelling adults","volume":"27","author":"Semba","year":"2013","journal-title":"J. Hum. Hypertens."},{"key":"2021111619131426300_B24","doi-asserted-by":"publisher","first-page":"e15534","DOI":"10.1371\/journal.pone.0015534","article-title":"Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile","volume":"5","author":"Lin","year":"2010","journal-title":"PLoS ONE"},{"key":"2021111619131426300_B25","doi-asserted-by":"publisher","first-page":"e24895","DOI":"10.1371\/journal.pone.0024895","article-title":"Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study","volume":"6","author":"Yan","year":"2011","journal-title":"PLoS ONE"},{"key":"2021111619131426300_B26","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/MCO.0b013e328346a326","article-title":"Fibroblast growth factor 21: effects on carbohydrate and lipid metabolism in health and disease","volume":"14","author":"Kralisch","year":"2011","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"2021111619131426300_B27","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.2337\/db10-0193","article-title":"Obesity is a fibroblast growth factor 21 (FGF21)-resistant state","volume":"59","author":"Fisher","year":"2010","journal-title":"Diabetes"},{"key":"2021111619131426300_B28","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nrendo.2012.258","article-title":"The role of hepatokines in metabolism","volume":"9","author":"Stefan","year":"2013","journal-title":"Nat. Rev. Endocrinol."},{"key":"2021111619131426300_B29","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrendo.2017.56","article-title":"Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance","volume":"13","author":"Meex","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"2021111619131426300_B30","doi-asserted-by":"publisher","first-page":"e87102","DOI":"10.1371\/journal.pone.0087102","article-title":"Novel insights into the cardio-protective effects of FGF21 in lean and obese rat hearts","volume":"9","author":"Patel","year":"2014","journal-title":"PLoS ONE"},{"key":"2021111619131426300_B31","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1210\/en.2011-1502","article-title":"PPARgamma agonist improves neuronal insulin receptor function in hippocampus and brain mitochondria function in rats with insulin resistance induced by long term high-fat diets","volume":"153","author":"Pipatpiboon","year":"2012","journal-title":"Endocrinology"},{"key":"2021111619131426300_B32","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.lfs.2011.02.003","article-title":"Effects of high-fat diet on insulin receptor function in rat hippocampus and the level of neuronal corticosterone","volume":"88","author":"Pratchayasakul","year":"2011","journal-title":"Life Sci."},{"key":"2021111619131426300_B33","doi-asserted-by":"publisher","first-page":"289","DOI":"10.12688\/f1000research.14117.1","article-title":"Defining \u2018FGF21 Resistance\u2019 during obesity: controversy, criteria and unresolved questions","volume":"7","author":"Markan","year":"2018","journal-title":"F1000 Res."},{"key":"2021111619131426300_B34","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1038\/ijo.2013.10","article-title":"Serum fibroblast growth factor 21 in human obesity: regulation by insulin infusion and relationship with glucose and lipid oxidation","volume":"37","author":"Str\u0105czkowski","year":"2013","journal-title":"Int. J. Obes."},{"key":"2021111619131426300_B35","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1038\/ncomms3019","article-title":"Fibroblast growth factor 21 protects against cardiac hypertrophy in mice","volume":"4","author":"Planavila","year":"2013","journal-title":"Nat. Commun."},{"key":"2021111619131426300_B36","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00380-014-0557-9","article-title":"Possible role of fibroblast growth factor 21 on atherosclerosis via amelioration of endoplasmic reticulum stress-mediated apoptosis in apoE(-\/-) mice","volume":"30","author":"Wu","year":"2015","journal-title":"Heart Vessels"},{"key":"2021111619131426300_B37","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1038\/srep02767","article-title":"Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue","volume":"3","author":"Liu","year":"2013","journal-title":"Sci. Rep."},{"key":"2021111619131426300_B38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/cvr\/cvu263","article-title":"Fibroblast growth factor 21 protects the heart from oxidative stress","volume":"106","author":"Planavila","year":"2015","journal-title":"Cardiovasc. Res."},{"key":"2021111619131426300_B39","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1139\/cjpp-2012-0441","article-title":"Proteomic study on the protective mechanism of fibroblast growth factor 21 to ischemia-reperfusion injury","volume":"91","author":"Cong","year":"2013","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"2021111619131426300_B40","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1111\/jcmm.12530","article-title":"FGF21 deletion exacerbates diabetic cardiomyopathy by aggravating cardiac lipid accumulation","volume":"19","author":"Yan","year":"2015","journal-title":"J. Cell. Mol. Med."},{"key":"2021111619131426300_B41","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.atherosclerosis.2016.07.929","article-title":"The relationship between the dietary inflammatory index and risk of total cardiovascular disease, ischemic heart disease and cerebrovascular disease: findings from an Australian population-based prospective cohort study of women","volume":"253","author":"Vissers","year":"2016","journal-title":"Atherosclerosis"},{"key":"2021111619131426300_B42","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.032703","article-title":"Ryanodine receptor calcium leak in circulating B-lymphocytes as a biomarker in heart failure","author":"Kushnir","year":"2018","journal-title":"Circulation"},{"key":"2021111619131426300_B43","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jacc.2018.04.053","article-title":"Association of IL-8 with infarct size and clinical outcomes in patients with STEMI","volume":"72","author":"Shetelig","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021111619131426300_B44","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1172\/JCI97192","article-title":"The cardiac lymphatic system stimulates resolution of inflammation following myocardial infarction","volume":"128","author":"Vieira","year":"2018","journal-title":"J. Clin. Invest."},{"key":"2021111619131426300_B45","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s10753-018-0729-3","article-title":"FGF-21 elevated IL-10 production to correct LPS-induced inflammation","volume":"41","author":"Li","year":"2018","journal-title":"Inflammation"}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20181099\/809815\/bsr-2018-1099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20181099\/809815\/bsr-2018-1099.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T20:11:15Z","timestamp":1637093475000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/38\/5\/BSR20181099\/88251\/Circulating-level-of-fibroblast-growth-factor-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,25]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10,31]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20181099","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,25]]},"article-number":"BSR20181099"}}